Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells

Area of Science:

• Immunology
• Endocrinology
• Regenerative Medicine

Background:

• Type 1 diabetes (T1D) is characterized by autoimmune destruction of pancreatic beta cells, leading to insulin deficiency.
• Preserving endogenous insulin secretion is a key goal for managing T1D and restoring glucose homeostasis.
• Mesenchymal stromal cells (MSCs) have shown potential in preclinical models for treating T1D.

Purpose of the Study:

• To evaluate the safety and efficacy of autologous MSC treatment in preserving beta-cell function in recent-onset T1D patients.
• To assess the impact of MSCs on residual insulin secretion as measured by C-peptide levels.

Main Methods:

• A prospective, randomized clinical study involving 20 adult patients with newly diagnosed T1D.
• Patients were randomized to receive either MSC treatment or a control intervention.
• Residual beta-cell function was assessed using C-peptide measurements during a mixed-meal tolerance test (MMTT) at 1-year follow-up.

Main Results:

• MSC-treated patients maintained or increased C-peptide peak values and area under the curve compared to the control group.
• Control group patients exhibited a decline in C-peptide levels over the 1-year study period.
• No adverse side effects were reported in the MSC treatment group.

Conclusions:

• Autologous MSC treatment is a safe and promising strategy for intervening in the progression of new-onset T1D.
• MSC therapy can preserve residual beta-cell function, offering potential for long-term glucose metabolism restoration.
• This cellular intervention warrants further investigation for T1D management.